Provided by Tiger Fintech (Singapore) Pte. Ltd.

Mersana Therapeutics Inc.

0.3269
-0.0278-7.84%
Post-market: 0.34320.0163+4.99%16:06 EDT
Volume:2.33M
Turnover:802.68K
Market Cap:40.74M
PE:-0.58
High:0.3640
Open:0.3430
Low:0.3262
Close:0.3547
Loading ...

Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
08 Feb

William Blair Initiates Coverage on Mersana Therapeutics With Outperform Rating

MT Newswires Live
·
06 Feb

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Not Doing Enough For Some Investors As Its Shares Slump 69%

Simply Wall St.
·
15 Jan

Mersana Therapeutics Inc : Guggenheim Cuts Target Price to $5 From $7

THOMSON REUTERS
·
13 Jan

Mersana Therapeutics selloff on data overdone, says BTIG

TIPRANKS
·
12 Jan

BTIG Sticks to Its Buy Rating for Mersana Therapeutics (MRSN)

TIPRANKS
·
11 Jan

Why Is Cancer-Focused Mersana Therapeutics Stock Trading Lower On Friday?

Benzinga
·
11 Jan

BUZZ-Mersana rises on FDA's 'fast track' tag for cancer drug, early-stage trial data

Reuters
·
10 Jan

Mersana Therapeutics' XMT-1660 Gains Additional US FDA Fast Track Designation

MT Newswires Live
·
10 Jan

Mersana Shares Rise on Advances With Breast-Cancer Treatment

Dow Jones
·
10 Jan

Mersana Therapeutics Shares up 22.3% at $1.59 Premarket on FDA's Fast Track Tag for Cancer Drug, Early Stage Trial Data

THOMSON REUTERS
·
10 Jan

Mersana Therapeutics Says Initial Data From Cancer Drug Trial Shows Promise, Shares Rise Premarket

MT Newswires Live
·
10 Jan

Mersana Therapeutics: FDA grants additional Fast Track designation to XMT-1660

TIPRANKS
·
10 Jan

Mersana Therapeutics: ‘Positive’ results from Phase 1 emiltatug ledadotin trial

TIPRANKS
·
10 Jan

Mersana Therapeutics Announces Additional FDA Fast Track Designation Granted to Emiltatug Ledadotin (Xmt-1660)

THOMSON REUTERS
·
10 Jan

Mersana Therapeutics Announces Additional FDA Fast Track Designation Granted to Emiltatug Ledadotin (XMT-1660)

GlobeNewswire
·
10 Jan

Mersana Therapeutics Announces Positive Initial Clinical Data From Phase 1 Clinical Trial of Emiltatug Ledadotin (Xmt-1660); Initiation of Expansion in Triple Negative Breast Cancer

THOMSON REUTERS
·
10 Jan

Mersana Therapeutics Inc - Emiltatug Ledadotin Generally Well Tolerated With Differentiated Safety Profile

THOMSON REUTERS
·
10 Jan

Mersana Therapeutics Announces Positive Initial Clinical Data from Phase 1 Clinical Trial of Emiltatug Ledadotin (XMT-1660); Initiation of Expansion in Triple Negative Breast Cancer

GlobeNewswire
·
10 Jan

Analysts Offer Insights on Healthcare Companies: ACELYRIN, INC. (SLRN), Cabaletta Bio (CABA) and Mersana Therapeutics (MRSN)

TIPRANKS
·
15 Nov 2024